GLP-1 medicines
Injections (and now tablets) that copy gut hormones controlling blood sugar and appetite. Same family, very different strengths. Social media calls them miracle drugs; the trials call them very effective, with fine print.
At a glance
- For
- Type 2 diabetes; weight management; some also lower heart attack and stroke risk or treat sleep apnoea
- Works
- Weight: from about 8% of body weight (liraglutide) to about 15% (semaglutide) and 15–21% (tirzepatide) over 1 to 1.5 years, versus 2–3% on a dummy treatment. Diabetes: HbA1c (3-month sugar average) down by roughly 1 to 2 points
- Cost
- PBS for type 2 diabetes only: Ozempic and Trulicity (criteria apply). None are on the PBS for weight loss, and Mounjaro isn’t on the PBS for anything (October 2026)
- Kicks in
- Appetite drops in the first weeks; doses stepped up about every 4 weeks; full effect over 1 to 1.5 years
- Taken for
- Long term: weight usually returns after stopping
- Watch for
- Nausea, vomiting, diarrhoea or constipation, reflux, gallstones
Not a miracle and not cheating: it’s a hormone. It turns down the food noise. Protein, sleep and moving are still your job.
Brand names
- Semaglutide: Ozempic (weekly injection, diabetes), Wegovy (weekly injection, weight), Rybelsus (daily tablet, diabetes). Semaglutide guide
- Tirzepatide: Mounjaro (weekly injection). Tirzepatide guide
- Liraglutide: Victoza (daily injection, diabetes); generic liraglutide for weight (the Saxenda brand left Australia in December 2025)
- Dulaglutide: Trulicity (weekly injection, diabetes)
- Exenatide: Byetta (stopped in Australia in 2022) and Bydureon (stopped in the US in 2024)
How it works
GLP-1 is a hormone your gut releases after eating. These medicines copy it and last much longer: they boost insulin when blood sugar is high, slow stomach emptying and tell the brain you’re full. Tirzepatide also copies a second gut hormone, GIP.
Used for
- Type 2 diabetes, alongside diet and exercise (all of them)
- Weight management in adults with obesity, or overweight with a weight-related condition (Wegovy, Mounjaro, liraglutide 3 mg)
- Lowering heart attack and stroke risk in people with heart disease and excess weight (Wegovy)
- Moderate to severe sleep apnoea with obesity (Mounjaro)
- Fatty liver disease with scarring (Wegovy; provisional approval in 2026)
Compared
Same idea, different strength and dosing. Weight figures are average loss in the main trial, on the medicine versus a dummy treatment, with diet and activity advice in both groups.
- GLP-1Semaglutide (Ozempic, Wegovy, Rybelsus)
- How taken
- Weekly injection, or a daily tablet on an empty stomach (Rybelsus)
- Approved for
- Type 2 diabetes; weight; lowering heart risk; fatty liver with scarring (provisional)
- Weight loss
- STEP 1 (Wegovy 2.4 mg): 14.9% vs 2.4% over 68 weeks
- Blood sugar
- HbA1c down 1.5–1.8 points over 40 weeks (SUSTAIN 7)
- PBS
- Ozempic for type 2 diabetes only
- Notable
- SELECT trial: about 20% fewer heart attacks, strokes or heart deaths in people with heart disease and excess weight
- GIP and GLP-1Tirzepatide (Mounjaro)
- How taken
- Weekly injection
- Approved for
- Type 2 diabetes; weight; sleep apnoea with obesity
- Weight loss
- SURMOUNT-1: 15.0–20.9% (by dose) vs 3.1% over 72 weeks
- Blood sugar
- HbA1c down by about 2 points
- PBS
- No, for any use
- Notable
- Beat semaglutide head-to-head for weight: 20.2% vs 13.7% over 72 weeks (SURMOUNT-5). Can make the contraceptive pill less reliable
- GLP-1Liraglutide (Victoza, generics)
- How taken
- Daily injection
- Approved for
- Type 2 diabetes (Victoza); weight (3 mg generics)
- Weight loss
- SCALE: 8.0% vs 2.6% over 56 weeks. In a head-to-head trial (STEP 8), weekly semaglutide caused more than twice as much weight loss
- Blood sugar
- Lowers HbA1c
- PBS
- No
- Notable
- The older daily option; generic versions approved in 2025
- GLP-1Dulaglutide (Trulicity)
- How taken
- Weekly injection
- Approved for
- Type 2 diabetes only
- Weight loss
- Not approved for weight. 2.3–3.0 kg over 40 weeks in diabetes (SUSTAIN 7)
- Blood sugar
- HbA1c down 1.1–1.4 points (SUSTAIN 7)
- PBS
- Yes, for type 2 diabetes
- Notable
- A long shortage (2022 onwards) has now resolved
- DiscontinuedExenatide (Byetta, Bydureon)
- How taken
- Twice-daily or weekly injection
- Approved for
- Type 2 diabetes
- Weight loss
- Modest
- Blood sugar
- Lowers HbA1c
- PBS
- No longer available in Australia
- Notable
- The first of the family, based on a hormone found in Gila monster saliva; now largely replaced
For the full weight-loss line-up, including tablets and pills still in trials, see weight-loss medicines compared.
Side effects
Gut side effects are the main ones, worst when starting and after each dose step, and usually settle. Eating smaller meals, stopping when full and going easy on fatty food helps.
Full side-effect list (from the product information)
How often, from the semaglutide (Ozempic) product information. Other GLP-1 medicines are similar; tirzepatide and liraglutide cause slightly more gut upset at weight-loss doses. Bold = serious.
Very common more than 1 in 10
- Nausea, vomiting, diarrhoea or constipation
- Tummy pain
- Headache
- Tiredness
- Low blood sugar, if also on insulin or a sulfonylurea
Common 1 in 10 to 1 in 100
- Dizziness
- Indigestion, reflux, burping, wind or bloating
- Gastritis
- Gallstones
- Hair thinning
- Injection-site reactions
- Low blood pressure
- Low blood sugar with other diabetes medicines
- Worsening of diabetic eye disease, if already present
Uncommon 1 in 100 to 1 in 1,000
- Pancreatitis (inflamed pancreas)
- Faster heart rate
- Dizziness on standing
- Altered taste
- Raised pancreatic enzymes on blood tests
Rare 1 in 1,000 to 1 in 10,000
- Anaphylaxis (severe allergic reaction)
- Angioedema (swelling of the face, lips or throat)
Very rare fewer than 1 in 10,000
- Sudden vision loss in one eye (NAION)
Frequency not known reported, rate unclear
- Bowel obstruction
Get help urgently if
- Severe tummy pain that won’t settle, sometimes going through to the back (possible pancreatitis)
- Pain under the right ribs, fever or yellow skin (possible gallstones)
- Vomiting or diarrhoea so bad you can’t keep fluids down (risk of dehydration and kidney problems)
- Swelling of the face or throat, or trouble breathing
- Shakiness, sweating or confusion if you also take insulin or a sulfonylurea (low blood sugar)
Good to know
- Muscle: in trials about a quarter to two-fifths of the weight lost was lean (non-fat) tissue, which includes muscle and water. Enough protein and strength exercise help protect muscle.
- “Ozempic face” isn’t a medical term. It’s facial fat loss after fast weight loss from any cause, not a special drug effect.
- Compounded copies have been banned in Australia since 1 October 2024. Online “semaglutide” or “tirzepatide” may be fake, contaminated or the wrong dose.
- Pregnancy: not used. Stop semaglutide at least 2 months, and tirzepatide at least 1 month, before trying to conceive.
- Supply: the Ozempic shortage (2022 to mid-2025) is over; new patients can start again.
- Not suitable with a personal or family history of medullary thyroid cancer or MEN2. Tell your doctor before any surgery or anaesthetic.
Common questions
Which GLP-1 medicine causes the most weight loss?
Tirzepatide, on current evidence. In a head-to-head trial, people lost 20.2% of their weight on tirzepatide versus 13.7% on semaglutide over 72 weeks. Individual results vary a lot.
Is “Ozempic face” real?
It isn’t a medical diagnosis. Fast weight loss from any cause, including diet or surgery, shrinks fat in the face and can make skin look looser. It isn’t a special effect of the drug.
Are compounded or online GLP-1 injections safe?
Compounding them has been banned in Australia since October 2024 because the copies aren’t checked for safety, strength or purity. Use only TGA-approved products from a pharmacy.
Does weight come back after stopping a GLP-1 medicine?
Usually, yes. A year after stopping semaglutide in the STEP 1 trial, people had regained about two-thirds of the weight they’d lost.
Can I use GLP-1 medicines in pregnancy?
No. Stop semaglutide at least 2 months and tirzepatide at least 1 month before trying to get pregnant. Tirzepatide can also make the contraceptive pill less reliable.
Information only. Not a recommendation or endorsement of any product. Whether a medicine suits you depends on your health and other medicines, so talk to your doctor or pharmacist. In an emergency, call 000 (Australia) or your local emergency number. From a mobile, 112 works in most countries.
More information
- STEP 1 trial: Semaglutide for weight management (NEJM)
- SURMOUNT-1 trial: Tirzepatide for obesity (NEJM)
- SURMOUNT-5: Tirzepatide versus semaglutide (American College of Cardiology)
- SCALE trial: Liraglutide 3 mg for weight management
- SUSTAIN 7: Semaglutide versus dulaglutide (Healio)
- SELECT trial: Semaglutide and heart outcomes (NEJM)
- STEP 1 extension: Weight regain after stopping semaglutide
- Australian Pharmacist: Ban on compounded GLP-1 medicines
- Diabetes Australia: Ozempic supply returning to normal (July 2025)
- TGA: Trulicity supply update
- TGA: Saxenda discontinuation
- WebMD: What is “Ozempic face”?
- Healthdirect: Medicines information
maladywise.com/medicines/glp1-medicines/